DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T-cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas.
poster
posted on 2024-12-15, 14:38 authored by Valentina Gambardella, Alastair Greystoke, Martin Reck, Meiruo Liu, Martha Mueller, Ulrich Duenzinger, Emily B Bergsland, Taofeek OwonikokoThe above is an infographic providing background on DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T-cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas.. Unless otherwise specified, the content for this infographic has undergone a medical, legal, and regulatory (MLR) review and approval process by Boehringer Ingelheim. Content developed with authors.
